Acadia Pharmaceuticals Adds Biotech Finance Veteran to Board
Event summary
- Jonathan M. Poole appointed to Acadia Pharmaceuticals' Board of Directors on March 3, 2026
- Poole will serve on the Audit Committee, bringing biopharmaceutical finance leadership experience
- Previously served as Senior VP of Finance at Vertex Pharmaceuticals and CFO roles at Evelo Biosciences and Genocea Biosciences
- Appointment aims to strengthen financial and operational expertise during Acadia's growth phase
The big picture
Acadia Pharmaceuticals is bolstering its board with finance expertise as it navigates a critical phase of commercial expansion and pipeline development. The appointment comes amid broader industry trends of biotech companies strengthening governance to support complex global operations and R&D diversification. Poole's background in scaling organizations through acquisitions and portfolio growth positions him to address Acadia's strategic priorities.
What we're watching
- Governance Dynamics
- How Poole's experience with global growth and acquisitions will influence Acadia's strategic decisions...
- Execution Risk
- Whether Acadia can sustain its commercial portfolio expansion while advancing its diverse pipeline...
- Financial Strategy
- The pace at which Poole will integrate his financial leadership into Acadia's growth strategy...
Related topics